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A bs tr ac t
Background
Carbamazepine causes various forms of hypersensitivity reactions, ranging from 
maculopapular exanthema to severe blistering reactions. The HLA-B*1502 allele has 
been shown to be strongly correlated with carbamazepine-induced Stevens–Johnson 
syndrome and toxic epidermal necrolysis (SJS–TEN) in the Han Chinese and other 
Asian populations but not in European populations.
Methods
We performed a genomewide association study of samples obtained from 22 subjects 
with carbamazepine-induced hypersensitivity syndrome, 43 subjects with carbamaze-
pine-induced maculopapular exanthema, and 3987 control subjects, all of European 
descent. We tested for an association between disease and HLA alleles through 
proxy single-nucleotide polymorphisms and imputation, confirming associations 
by high-resolution sequence-based HLA typing. We replicated the associations in 
samples from 145 subjects with carbamazepine-induced hypersensitivity reactions.
Results
The HLA-A*3101 allele, which has a prevalence of 2 to 5% in Northern European 
populations, was significantly associated with the hypersensitivity syndrome 
(P = 3.5×10−8). An independent genomewide association study of samples from sub-
jects with maculopapular exanthema also showed an association with the HLA-
A*3101 allele (P = 1.1×10−6). Follow-up genotyping confirmed the variant as a risk 
factor for the hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval 
[CI], 1.27 to 121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 
19.36), and SJS–TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).
Conclusions
The presence of the HLA-A*3101 allele was associated with carbamazepine-induced 
hypersensitivity reactions among subjects of Northern European ancestry. The presence 
of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the 
risk from 5.0% to 3.8%. (Funded by the U.K. Department of Health and others.)
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Carbamazepine is one of the most commonly prescribed drugs for the treat-ment of epilepsy, as well as trigeminal neu-
ralgia and bipolar disorder. A minority of treated 
persons have hypersensitivity reactions that vary 
in prevalence and severity,1 with some forms as-
sociated with substantial morbidity and mortal-
ity. The mildest form, maculopapular exanthema, 
occurs in 5 to 10% of treated persons of Euro-
pean ancestry and resolves spontaneously after 
drug discontinuation. More severe reactions, such 
as the hypersensitivity syndrome, are associated 
with mortality of up to 10%2 and include symp-
toms such as rash, fever, eosinophilia, hepatitis, 
and nephritis. The most severe reactions, such as 
the Stevens–Johnson syndrome (SJS) and toxic epi-
dermal necrolysis (TEN), are characterized by a 
blistering rash affecting a variable percentage of 
the body-surface area. The rate of death increases 
with the degree of epidermal detachment. TEN is 
the rarest of these phenotypes and is associated 
with mortality of up to 30%. According to the 
labeling of carbamazepine, as mandated by the 
Food and Drug Administration (FDA), the estimat-
ed incidence of SJS–TEN is 1 to 6 cases in 10,000 
persons of European ancestry who are exposed 
to the drug.
Genomewide approaches are increasingly used 
to identify genetic predisposing factors for drug-
induced hypersensitivity reactions and drug-
induced liver injury.3 For example, the HLA-
B*1502 allele has been identified as a clinically 
important predictor of SJS–TEN in Asians of Han 
Chinese descent who are candidates for treat-
ment with carbamaz e pine.4 This finding led the 
FDA to require a warning label for carbamazepine 
to indicate the need for genotyping for HLA-
B*1502 before the drug is prescribed. This change 
seems warranted, given the prospective study 
described in this issue of the Journal,5 which 
shows that withholding carbamazepine from 
subjects of Han Chinese ancestry who carry the 
HLA-B*1502 allele substantially decreased the 
rate of the development of SJS–TEN. The value of 
HLA-B*1502 in predicting the risk of SJS–TEN 
has been shown in other Asian populations, in-
cluding those of Thailand, Malaysia, and India.4,6-8 
This effect is specific for SJS–TEN, as compared 
with the full spectrum of carbamazepine-related 
hypersensitivity reactions, which led to the sug-
gestion that different phenotypes of carbamaze-
pine-induced hypersensitivity may have distinct 
genetic predictors. Furthermore, HLA-B*1502 is 
rare (with a prevalence of less than 2%) in popu-
lations of European descent, in which carbamaz-
epine-induced SJS–TEN occurs at a lower inci-
dence than in Asian populations.9-12 Using a 
candidate-gene approach, previous studies have 
shown weak or moderate signals of association 
between maculopapular exanthema or the DRESS 
(drug reaction with eosinophilia and systemic 
symptoms) syndrome and single-nucleotide poly-
morphisms (SNPs) in the major histocompatibil-
ity complex (MHC) region,13-15 and these asso-
ciations have not been consistently replicated.13,14
We present data from two independent studies 
that suggest the relevance of an HLA variant to 
the clinical spectrum of carbamazepine-related 
hypersensitivity reactions, including maculopap-
ular exanthema, the hypersensitivity syndrome, 
and SJS–TEN.
Me thods
Case Subjects
Recruitment
We recruited case subjects at centers collaborat-
ing with the University of Liverpool and Walton 
Centre for Neurology (both hereinafter referred 
to as “the Liverpool collaborators”) or at centers 
affiliated with the EPIGEN consortium (for de-
tails, see the Supplementary Appendix, available 
with the full text of this article at NEJM.org). All 
case subjects and control subjects were of Euro-
pean ancestry as determined by either self-report 
or genetic-marker analysis.13 Many of these sub-
jects have been described previously in the con-
text of hypersensitivity reactions.9,13,16
Hypersensitivity Syndrome
The group with the hypersensitivity syndrome 
consisted of 26 subjects: 23 who were recruited 
through the Liverpool collaborators and 3 who 
were recruited through the EPIGEN consortium. 
The hypersensitivity syndrome was defined as 
the presence of rash or liver involvement within 
3 months after the initiation of carbamazepine 
treatment, accompanied by a minimum of two of 
the following manifestations: a prolonged recov-
ery phase, despite withdrawal of the drug; fever; 
involvement of other internal organs (liver, kidney, 
lung, central nervous system, heart, muscle, thy-
The New England Journal of Medicine 
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roid, or lymphoid system); or the presence of he-
matologic abnormalities, such as eosinophilia 
and atypical lymphocytosis.17 We considered the 
DRESS syndrome to be the same as the hyper-
sensitivity syndrome.
Acute Generalized Exanthematous Pustulosis
We recruited one subject with acute generalized 
exanthematous pustulosis (AGEP), who had a 
typical pustular reaction with high fever,18 from 
a collaborating clinic in Switzerland. We then 
analyzed the data from this subject together with 
data from the subjects with the hypersensitivity 
syndrome.
Maculopapular Exanthema
The group with maculopapular exanthema con-
sisted of 106 subjects: 57 who were recruited 
through the Liverpool collaborators and 49 who 
were recruited through the EPIGEN consortium. 
Maculopapular exanthema was defined as rash 
without systemic symptoms that required the dis-
continuation of carbamazepine within 3 months 
after the initiation of drug therapy.
SJS–TEN
The SJS–TEN group consisted of 12 subjects: 8 who 
were recruited through the Liverpool collaborators 
and 4 who were recruited through the EPIGEN 
consortium. The diagnostic criteria suggested by 
the RegiSCAR Project (a research network for se-
vere cutaneous adverse drug reactions)11,19 were 
used for this group (see the Supplementary Ap-
pendix).
Control Subjects
Population Controls
Genotype data from the Wellcome Trust Case 
Control Consortium (WTCCC) (www.wtccc.org 
.uk) were used as a population control group. The 
Liverpool collaborators used data from a genome-
wide association study of samples from 2691 
subjects in the U.K. National Blood Services Col-
lection. EPIGEN used samples from a homoge-
neous subgroup of 1296 subjects in the 1958 Brit-
ish Birth Cohort that were selected by principal 
component analysis. We did not screen either set 
of population controls for carbamaze pine-related 
adverse drug reactions. (For details about our 
access to these data, see the Supplementary Ap-
pendix.)
Clinical Controls
The clinical control group consisted of 257 sub-
jects with epilepsy who had been taking carba-
mazepine for at least 3 months with no clinical 
or biochemical signs of hypersensitivity. Of these 
subjects, 44 were recruited by the Liverpool col-
laborators and 213 were recruited from clinics 
affiliated with EPIGEN.
Genomewide Genotyping
Genomewide analysis of samples that were ini-
tially available from the 22 Liverpool subjects 
with carbamazepine-induced hypersensitivity syn-
drome was performed with the use of the Illu-
mina Infinium 1.2M chip at the Wellcome Trust 
Sanger Institute. Samples from 43 case subjects 
and 200 control subjects from the EPIGEN con-
sortium were genotyped with the use of the Illu-
mina 610K Quad platform at the Duke University 
Center for Human Genome Variation. (Details 
regarding quality controls and principal-compo-
nents analysis are provided in the Supplementary 
Appendix.)
Imputation of HLA Alleles
We based the imputation of classic HLA alleles in 
samples from the 22 Liverpool subjects with the 
hypersensitivity syndrome and control subjects 
from the U.K. National Blood Service on a dense 
reference panel of SNP data and four-digit HLA 
types in 2767 unrelated subjects of European de-
scent, according to a method described recently.20 
We imputed classic HLA alleles in the samples 
from the EPIGEN consortium, using MACH 1.0 on 
the Web site of the Center for Statistical Genetics 
(www.sph.umich.edu/csg/abecasis/MACH).21 The 
1458 subjects in the HLA-typed 1958 British Birth 
Cohort constituted the reference population. (See 
the Supplementary Appendix for further details.) 
We used different approaches to impute the HLA 
alleles in the Liverpool and EPIGEN subjects, 
because the two studies were originally inde-
pendent.
HLA-A High-Resolution Genotyping
To confirm the accuracy of imputation, high-
resolution, sequence-based HLA-A typing of sam-
ples from 22 subjects with the hypersensitivity 
syndrome and from a subgroup of 44 clinical 
control subjects (i.e., subjects who did not have 
adverse reactions to carbamazepine) was per-
The New England Journal of Medicine 
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formed by Histogenetics. We determined the 
HLA-A alleles in samples from 49 subjects with 
maculopapular exanthema and a subgroup of 213 
clinical control subjects from the EPIGEN consor-
tium, using sequence-specific polymerase-chain-
reaction assay primers (details available on request). 
Direct genotyping showed 100% concordance 
with the imputed alleles.
HLA-A*3101 Proxy SNP Genotyping
Genotyping of the rs1061235 SNP in samples 
from all Liverpool subjects (including case sub-
jects with maculopapular exanthema, the hyper-
sensitivity syndrome, or SJS–TEN and clinical 
control subjects) was performed by KBioscience. 
This allele has previously been shown to be in 
complete linkage disequilibrium (r2 = 1) with the 
HLA-A*3101 allele in populations of European 
descent.22
Statistical Analysis
Statistical analyses were performed with the use 
of PLINK (version 1.05),23 RevMan (version 5) 
(http://ims.cochrane.org/revman), and Haploview24 
software packages. For the genomewide associa-
tion studies, both the Liverpool collaborators and 
the EPIGEN consortium used logistic regression 
with an additive model of inheritance. They ad-
justed for population stratification by including 
significant principal components as covariates in 
the logistic-regression model and used a P value 
of less than 5.0×10−8 to indicate genomewide sig-
nificance. Pooled analysis of the different groups 
of subjects was performed to estimate odds ratios 
and confidence intervals from summary data with 
the use of a random-effects model. Between-study 
heterogeneity was tested by calculating I2 and 
Tau.2 The z-score directionality or estimated risk 
was checked for consistency with observed data.
R esult s
Association with the Hypersensitivity 
Syndrome
We first conducted an association analysis in-
volving 1.2M SNPs in samples from the 22 Liver-
pool subjects with carbamazepine-induced hy-
persensitivity syndrome and from 2691 healthy 
controls from the U.K. National Blood Services 
Collection. (The full set of results can be obtained 
from the European Genotype Archive, access num-
ber EGAS00000000037.) We identified a strong 
signal in the MHC region on chromosome 6, with 
several SNPs around HLA-A reaching genome-
wide significance (P = 3.5×10−8) (Fig. 1A and 1B). 
This variant was seen in 40.0% of case subjects 
but in only 4.9% of control subjects. The top hit 
(rs1061235) had previously been shown to be a 
proxy for the HLA-A*3101 allele in persons of 
European descent.22 Therefore, we focused on 
this locus as a predictor of response through 
high-resolution, sequence-based HLA-A typing, 
which confirmed the absolute correlation (r2 = 1) 
between rs1061235 and HLA-A*3101 that had 
been observed previously.22 No other classic HLA-A 
alleles reached nominal significance (Table 1 in 
the Supplementary Appendix).
During the course of this study, samples from 
4 additional subjects with the hypersensitivity 
syndrome and from 1 additional subject with 
AGEP became available from the Liverpool and 
EPIGEN centers. Of these 5 subjects, 2 (including 
the single subject with AGEP) tested positive for 
HLA-A*3101. A comparison of all 27 subjects with 
the 257 control subjects without adverse drug 
reactions produced an odds ratio of 12.41 (95% 
confidence interval [CI], 1.27 to 121.03; P = 0.03) 
(Fig. 2).
Association with Maculopapular Exanthema
EPIGEN investigators performed a genomewide 
association study of samples from 43 subjects 
with maculopapular exanthema and 1296 healthy 
control subjects from the 1958 British Birth Co-
hort. (The full set of results can be obtained from 
dbGAP, access number EGAS00000000036.) HLA-
A*3101 was the most strongly associated allele 
(P = 1.11×10−6) and was observed in 27% of case 
subjects and 4% of control subjects, although the 
effect was not significant genomewide (Fig. 3 in 
the Supplementary Appendix). However, we had ac-
cess to another 63 case subjects with maculopap-
ular exanthema and 257 control subjects without 
adverse drug reactions. Our combined analysis of 
all 106 subjects with maculopapular exanthema 
and the 257 clinical control subjects showed a 
significant allelic association with HLA-A*3101 
(P = 8.0×10−7), generating an odds ratio of 8.33 
(95% CI, 3.59 to 19.36) (Fig. 2). Although the 
analyses of samples from subjects with maculo-
papular exanthema and those with the hypersen-
sitivity syndrome were carried out in the Nether-
The New England Journal of Medicine 
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Figure 1. Results of a Genomewide  Association Study of Samples from Case Subjects with Carbamazepine-Induced 
Hypersensitivity  Syndrome and Control Subjects.
Panel A shows a Manhattan plot for logistic regression with a strong signal in the HLA-A region on chromosome 6. 
Each dot represents a P value for the comparison of 22 case subjects with the hypersensitivity syndrome and 2691 
healthy control subjects from the Wellcome Trust Case Control Consortium. Panel B shows P values for single-nu-
cleotide polymorphisms (SNPs) in the HLA-A region. There is a strong association between carbamazepine-induced 
hypersensitivity syndrome and the HLA-A*3101 allele, with identification of the allele in 40.0% of case subjects and 
only 4.9% of control subjects. The x axis shows the SNP position on chromosome 6 (National Center for Biotechnol-
ogy Information build 36). The left y axis shows the negative log10 of P values for the comparison between case sub-
jects and control subjects, as calculated with logistic regression. The right y axis shows the recombination rate on 
chromosome 6 between 29 and 31 Mb. The diamonds show the degree of linkage disequilibrium (LD) in the samples.
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lands and Liverpool, respectively, the effect size 
of HLA-A*3101 on risk was consistent across the 
EPIGEN and U.K. groups.
Association with SJS–TEN
On the basis of our hypothesis that the HLA-
A*3101 allele is associated with carbamazepine-
induced SJS–TEN, we genotyped HLA-A*3101 in 
a group of 12 subjects with SJS–TEN who were 
recruited from both the Liverpool and EPIGEN-
affiliated centers. Of these 12 subjects, 5 (42%) 
carried the allele, as compared with 10 (4%) of the 
257 clinical control subjects (odds ratio, 25.93; 
95% CI, 4.93 to 116.18; P = 8.0×10−5) (Fig. 2).
A pooled analysis of all 145 subjects with 
carbamazepine-induced hypersensitivity and 257 
control subjects without adverse drug reactions 
showed a strong association between hypersen-
sitivity and the HLA-A*3101 allele (odds ratio, 
9.12; 95% CI, 4.03 to 20.65; P = 1.0×10−7). On the 
basis of this pooled collection, we calculated 
that the presence of HLA-A*3101 had a sensitiv-
ity of 26% and a specificity of 96% as a predic-
tor of carbamazepine-associated hypersensitivity. 
Given that carbamazepine hypersensitivity has a 
prevalence of 5% (1:20), application of the test 
criteria from our pooled analysis would increase 
the post-test probability to 26% (approximately 
1:4) on the basis of the positive likelihood ratio 
of 6.74 (95% CI, 3.51 to 13.00). Since the nega-
tive likelihood ratio was 0.77 (95% CI, 0.67 to 
0.84), a negative HLA-A*3101 test would reduce 
the probability of hypersensitivity from 5.0% to 
3.8% (1:26 ratio).
Discussion
We found that a variation in the presence of the 
HLA-A*3101 allele is an important predictor of 
the full spectrum of carbamazepine-induced hy-
persensitivity reactions in persons of European 
descent. Such reactions range from the relatively 
mild but nevertheless troublesome maculopapu-
lar exanthema to more severe reactions, such as 
the hypersensitivity syndrome and SJS–TEN. Al-
though the presence of the HLA-A*3101 allele is 
neither necessary nor sufficient for the develop-
ment of hypersensitivity to carbamazepine, it is 
associated with a significantly increased risk.
Our data add to growing evidence of the role 
of different HLA alleles in predisposing patients 
to immune-mediated adverse reactions, such as 
drug-induced hypersensitivity 4,25-27 and liver in-
jury.3,28 The most prominent example thus far is 
the strong predictive value of the HLA-B*5701 
allele for hypersensitivity to the drug abacavir, 
used for the treatment of human immunodefi-
ciency virus infection.25,26,29 FDA guidelines now 
recommend HLA-B*5701 testing in advance of 
abacavir prescription. Testing results in a reduc-
tion in the incidence of abacavir hypersensitivi-
ty27,30 and is cost-effective.29,31
Our study now provides strong evidence sug-
gesting that HLA-A*3101 is a predictor of carba-
mazepine hypersensitivity in Europeans. First, 
despite the small number of subjects who were 
included in the analysis, this signal had genome-
wide significance. Second, the signal was ob-
served across independent groups of case subjects 
with different phenotypes of carbamazepine hy-
persensitivity, with the use of independent sets 
of control subjects. Third, HLA-A*3101 has pre-
viously been shown to be associated with multiple 
carbamazepine-hypersensitivity phenotypes, in-
cluding SJS–TEN in Japanese subjects15,32 and 
with carbamazepine-induced maculopapular ex-
anthema in subjects of Han Chinese ancestry.14 
The one subject in our study who had AGEP, a 
reaction characterized by sterile pustules, neutro-
philic inflammation, and high levels of interleu-
kin-8 in skin,33 also was found to carry the 
HLA-A*3101 allele. The prevalence of this allele is 
2 to 5% in Northern European populations, 2% 
in Han Chinese populations, and 9% in Japanese 
populations.32,34,35 The finding that HLA-A*3101 
is associated with carbamazepine-induced hyper-
sensitivity in populations of different ancestries 
parallels the finding of HLA-B*5701-associated 
abacavir hypersensitivity.30,36
HLA-B*1502, a predictor of carbamazepine 
hypersensitivity reactions in Asian populations, 
seems to be phenotype-specific in that it pre-
dicts the development of SJS–TEN but not the 
development of the hypersensitivity syndrome or 
maculopapular exanthema.14 This finding has led 
to the suggestion that the pathogenesis of carba-
mazepine-induced SJS–TEN is distinct from that 
of the hypersensitivity syndrome. This hypothe-
sis is based on the fact that class I alleles are 
usually associated with specific CD8+ cytotoxic 
T-cell reactions, which is consistent with the 
known pathologic features of SJS–TEN.37 How-
The New England Journal of Medicine 
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ever, our data suggest that the class I allele HLA-
A*3101 may be important for an increased range 
of phenotypes, including maculopapular exan-
thema and the hypersensitivity syndrome, at least 
in European populations. Persons with carba-
mazepine-induced hypersensitivity syndrome have 
been shown to have several types of drug-specif-
ic T cells in peripheral blood, including CD4+, 
CD8+, and CD4-CD8+ cells.38 Although there is 
no obvious relationship between HLA-A*3101 
and HLA-B*1502, reports have indicated a possi-
ble overlap in peptide-binding specificity.39 Giv-
en the degree of linkage disequilibrium across 
the extended MHC region, we cannot be certain 
that either HLA-B*1502 or HLA-A*3101 is causal.
We used samples from healthy volunteers in 
the WTCCC as control subjects for both ge-
nomewide association studies. Given that the 
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Figure 2. Distribution of the HLA-A*3101 Allele across the Spectrum of Clinical Phenotypes of Case Subjects with Carbamazepine- 
Induced Hypersensitivity and Control Subjects without Adverse Reactions to Carbamazepine.
Subjects were recruited at centers collaborating with the University of Liverpool and Walton Centre for Neurology (UK) or centers affili-
ated with the EPIGEN consortium. The sample obtained from one patient with acute generalized exanthematous pustulosis (AGEP) was 
analyzed with the samples for the group of case subjects with the hypersensitivity syndrome. Since there were no observations of the 
HLA-A*3101 allele in the three case subjects with the hypersensitivity syndrome in the EPIGEN cohort, 0.5 was added to each value in a 
two-by-two contingency table to estimate an odds ratio. One patient with the Stevens–Johnson syndrome and toxic epidermal necrolysis 
(SJS–TEN) was of mixed European and Thai ancestry. Study weighting (indicated by different sizes of squares) refers to the proportion  
of subjects who were recruited from each study cohort. Diamonds indicate pooled odds ratios. The horizontal lines indicate 95% confi-
dence intervals. The abbreviation df denotes degrees of freedom, and I2 is the percentage of total variation that is due to heterogeneity 
rather than chance.
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hypersensitivity syndrome occurs in 1 in 5000 to 
1 in 10,000 persons, it is unlikely that more than 
one or two population control subjects would be 
at risk for hypersensitivity with exposure to car-
bamazepine. The larger WTCCC collections there-
fore afforded increased power over that provided 
by comparison of case subjects with the clinical 
control subjects. Nevertheless, in analyses involv-
ing the 257 clinical control subjects, the associa-
tion with HLA-A*3101 remained strong for both 
the hypersensitivity syndrome (odds ratio, 12.41; 
95% CI, 1.27 to 121.03) and SJS (odds ratio, 
25.93; 95% CI, 4.93 to 116.18), although the ef-
fect size was smaller with maculopapular exan-
thema (odds ratio, 8.33; 95% CI, 3.59 to 19.36).
Additional studies in populations of Europe-
an descent and other ancestry are required to 
further characterize this association. The Inter-
national Serious Adverse Event Consortium is 
coordinating a global effort to recruit subjects 
with drug-induced severe adverse events (www 
.saeconsortium.org). Efforts such as this will fa-
cilitate the analysis of larger groups of subjects, 
which may well uncover other genetic variants 
associated with a smaller effect size or popula-
tion-specific variants. Additional work is also 
required to determine whether the effect of the 
HLA-A*3101 allele is specific to carbamazepine 
or whether it also applies to other drugs. A pro-
spective study that is based on the results we 
present here would facilitate the routine clinical 
use of HLA-A*3101 testing in carbamazepine 
treatment. In this issue of the Journal, a report 
describes how prospective HLA-B*1502 typing 
can prevent carbamazepine-induced SJS–TEN in 
Han Chinese populations.5
We propose that HLA-A*3101 is clinically rele-
vant as a marker to predict hypersensitivity reac-
tions. On the assumption that the prevalence of 
carbamazepine-induced hypersensitivity is 5.0%, 
the presence of the HLA-A*3101 allele increases 
the risk of hypersensitivity to 26.0%, whereas its 
absence reduces the risk to 3.8%. Among Japa-
nese patients, the estimated reduction is from 
2.9% to 1.1%. The sensitivity and specificity 
values estimated here for Europeans (26% and 
96%) and by others for Japanese populations 
(61% and 88%)32 vary. Among a number of pos-
sible reasons for these differences are differences 
in study size, in the frequency of HLA-A*3101 
(and potential interacting variation), and in the 
effect size of the allele across the two populations. 
Nonetheless, these numbers are similar to those 
underlying the test criteria calculated for the 
presence of the HLA-B*5701 allele and abacavir 
hypersensitivity (sensitivity, 45.5%; specificity, 
97.6%; and a risk reduction from 7.8% to 2.7%).
On the basis of our data, we have calculated 
that 83 patients would need to be screened to 
prevent one case of carbamazepine hypersensi-
tivity; the number in the Japanese population is 
56. However, it is important to note that this 
calculation is based on a conservative estimate 
of the prevalence of carbamazepine hypersensitiv-
ity (5%). The prevalence of carbamazepine-in-
duced hypersensitivity that was determined in the 
context of the Standard and New Antiepileptic 
Drugs (SANAD) trial (Current Controlled Trials 
number, ISRCTN38354748) (also involving subjects 
of European descent) was 10%.40 On the basis of 
this prevalence, the number of persons who 
would need to be screened to prevent one in-
stance of carbamazepine-induced hypersensitiv-
ity is 39. We therefore suggest that consideration 
be given to adding the association with HLA-
A*3101 to the drug label for carbamazepine.
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Methods 
Recruiting centres 
University of Liverpool collaborators included the UK national prospective SANAD study, the 
EUDRAGENE study and Universitätsspital Bern (Switzerland). The EPIGEN Consortium includes Duke 
University (North Carolina), University College London (UK), Université Libre de Bruxelles (Brussels, 
Belgium) and the Royal College of Surgeons and Beaumont Hospital in Dublin, Ireland.  
Definition of Stevens Johnson Syndrome 
SJS was defined as skin detachment 1-10% (SJS), 10-30% (overlap syndrome) and >30% (TEN), the 
presence of atypical target lesions predominately on the trunk and face, severe, often haemorrhagic, 
erosions of mucous membranes. Other manifestations indicating systemic involvement included fever, 
liver chemistry elevations, intestinal and pulmonary manifestations, presence of lymphopenia). 
Data access for healthy controls 
Individual-level genotype data (Illumina 1.2M (custom chip) were accessed for both sets of healthy 
controls by application to the Wellcome Trust Case Control Consortium Data Access Committee 
(https://www.wtccc.org.uk/ccc1/access_to_data_samples.shtml). 
 
Details on cleaning of Illumina data 
Illumina 1.2M on 22 HSS cases: The Illumina gender markers were utilized to compare clinical data with 
the DNA sample gender. Hardy-Weinberg equilibrium was estimated and SNPs which failed (p< 0.0001) 
in control population were excluded from further analyses. In addition, SNPs with MAF <1% and SNPs 
with genotype success rate < 97% were excluded. Final Manhattan plot cleansing step was based on low 
intensities and regional LD estimates. Accurate annotation of the variant names and strand orientation 
by explicit specification of the version of the human genome assembly and of dbSNP ensured 
compatibility of different datasets for comparison in pooled analysis of case-control studies. 
Illumina 610k on 49 EPIGEN MPE cases: All quality control measures were performed using PLINK. All 
SNPs with a genotyping success rate < 90%, those with MAF < 2% and subjects with genotyping success 
rate < 95% were excluded from the dataset. SNPs that were outside a Hardy-Weinberg Equilibrium 
threshold of p<0.0001 in control subjects were also removed. To correct for potential cryptic 
relatedness, the dataset was thinned to SNPs in linkage equilibrium (SNPs with r2<0.25) and identity-by-
descent of overall genome was calculated with a cut-off threshold of 12% shared with another 
individual. Population structure was determined by principal components analysis and outliers were 
removed. 
 
 
Details of imputation of HLA alleles in EPIGEN Consortium samples: 
We imputed HLA types across 5 loci (HLA-A, B, C, DR, DQ) to the level of 4 digits maximum. To achieve 
this, our full GWAS dataset was reduced to SNPs within the HLA locus (NCBI Build 36, base positions 
25760204 to 33529555 on chromosome 6). All MPE cases and CBZ-tolerant controls were imputed 
together as one population. .  Background European HLA allele frequencies were obtained from 
www.allelefrequencies.net 21 and through the Irish Blood Transfusion Service Bone Marrow Registry  22.  
The quality of the imputation by MACH is described by an r2 value for each HLA type imputed. The 
quality threshold was set to r2>0.9. Summary information and quality scores per HLA type imputed are 
available upon request. 
 
Background European HLA allele frequencies were obtained from www.allelefrequencies.net21 and 
through the Irish Blood Transfusion Service Bone Marrow Registry22 
HLA-A *3101 SSP genotyping: 
In order to validate the association with the imputed HLA-A*3101 (in EPIGEN samples), we performed 
an established wet lab technique to confirm the presence of HLA alleles by amplification of genomic 
DNA with sequence specific primers (SSP) in a polymerase chain reaction. Sequence-specific primers for 
HLA-A*3101 were obtained with kind permission from Mary N. Carrington of the National Cancer 
Institute- Frederick (Maryland, USA) for detecting HLA-A*3101 across the entire EPIGEN cohort. The 
forward primer sequence is 5’-GATAGAGCAGGAGAGGCCT-3’ and the reverse primer sequence is 5’-
AGCGCAGGTCCTCGTTCAA-3’. Visualisation of confirmatory bands was possible by placing an electric 
current across a 2% agarose gel containing the samples (see Figure 4 below). 
All samples were correctly imputed as each HLA-A*3101 allele carrier was positively identified by the 
SSP typing method. 
Details of population stratification 
Principle component analysis was performed to assess genetic markers for ethnicity. All participants 
were self reported Caucasans. Only individuals with genetically matching Caucasian ethnicity were 
included into the association analysis. We were working with Phase 1 1958 controls (n=1500), we 
removed 204 outliers from PCA plot leaving us with 1296 samples for case/control analysis.  PCA plots 
for Liverpool HSS (n=22) in conjunction with healthy controls (n=2291) and EPIGEN MPE and EPIGEN 
controls are shown in Supp Fig 1 and Supp Fig 2 below respectively. 
 Results 
Table 1. High resolution sequence-based HLA-A typing in patients with carbamazepine (CBZ)-induced 
hypersensitivity syndrome and CBZ-tolerant patients.  
HLA 
allele‡ 
CBZ-
tolerant 
controls 
Allelic Hypersensitive 
patients 
Allelic P-value Odds Ratio  
Frequency Frequency   (95% CI) 
A*0101g§ 17 0.19 12 0.27 0.3729 1.57 (0.6703-3.6595) 
A*0201g 21 0.24 8 0.18 0.511 0.71 (0.2855-1.7605) 
A*0301g 11 0.13 0 0 0.0601 0.08 (0.0044-1.3157) 
A*1101g 11 0.13 3 0.07 0.3839 0.51 (0.1352-1.9399) 
A*2301g 2 0.02 0 0 1 0.39 (0.0183-8.2745) 
A*2402g 3 0.03 5 0.11 0.1162 3.63 (0.8263-15.969) 
A*2403g 
0 0 1 0.02 0.2576 6.10 (0.2436-
152.9367) 
A*2501g 5 0.06 1 0.02 0.6631 0.39 (0.0437-3.4093) 
A*2601g 6 0.07 2 0.05 0.7182 0.65 (0.1259-3.365) 
A*2608 1 0.01 0 0 1 0.66 (0.0262-16.419) 
A*3001g 3 0.03 0 0 0.6622 0.27 (0.0139-5.4331) 
A*3002 1 0.01 0 0 1 0.66 (0.0262-16.419) 
A*3101g 
1 0.01 8 0.18 0.00064 19.33 (2.3325-
160.2439) 
A*3201 3 0.03 1 0.02 1 0.66 (0.0665-6.5245) 
A*3303g 
0 0 2 0.05 0.1078 10.41 (0.489-
221.697) 
A*6801 
0 0 1 0.02 0.2576 6.10 (0.2436-
152.9367) 
A*6801g 3 0.03 0 0 0.6645 0.27 (0.0139-5.4331) 
Total 
alleles 
88   44       
‡
Antigen recognition site allele 
§
Alleles bearing suffix 'g' in A locus have identical sequences in exon 2 and exon 3 antigen recognition 
sites. 
 
An association between HSS and HLA-A*3101 presence was identified (OR 24.6; 95% CI 2.8, 214.0); 
P=0.00004). No other HLA-A alleles showed statistically different allelic frequencies. 
 
 Figure 1. Population stratification detection using GWAS in WTCCC and patients with hypersensitivity 
syndrome (HSS) 
 
  
Figure 2. Population stratification detection using GWAS within the cohort of maculopapular exanthema 
(MPE) cases from the EPIGEN consortium and healthy controls from the 1958 cohort. All participants 
were self reported Europeans. Ethnicity was reported orally to clinician during investigations and 
recorded in clinical notes. 
Principal Components Analysis was performed to reduce subjects to a homogenous cluster of apparent 
northern European ethnicity. The final cohort is shown below. 
 
 Figure 3. Results of MPE GWAS analysis 
 
GWAS analysis involving MPE cases (n=43) and healthy controls from the 1958 British Birth Cohort 
(n=1296). Significant EIGENSTRAT covariates are included as covariates in logistic regression model. The 
top hit on chromosome six is HLA*3101 (P = 1.11 x 10-6). 
 
 
 
 
 
 
 
 
Figure 4: Selection of imputed HLA-A*3101 samples following PCR amplification with sequence specific 
primers.  
 
Imputed positive sample lanes 1-4 contained a strong gel band as confirmation whereas the imputed 
negative sample shown here in lane 5 contained no band. 
